AUG 12, 2026 · PHASE 2 TRIAL
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
ClinicalTrials.gov
This is a Phase 2 trial registration with no results reported; the study is actively recruiting and designed to evaluate safety, tolerability, and a surrogate biomarker endpoint in a rare population.
Reported
Estimated enrollment58
Primary outcome measureChange from baseline in brain amyloid burde…
Primary outcome assessment periodUp to 24 months